ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zan...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-04, Vol.16 (10), p.517-523 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 523 |
|---|---|
| container_issue | 10 |
| container_start_page | 517 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Hillmen, Peter Brown, Jennifer R Eichhorst, Barbara F Lamanna, Nicole O'Brien, Susan M Qiu, Lugui Salmi, Tommi Hilger, James Wu, Kenneth Cohen, Aileen Huang, Jane Tam, Constantine S |
| description | Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting. |
| doi_str_mv | 10.2217/fon-2019-0844 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2473392640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473392640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-ca6b7064c24f907885f5dacd6d1903dffdeffe47c3de6fd2242ad0477bbd61e33</originalsourceid><addsrcrecordid>eNp1kEtPAyEURonRWK0u3ZpJXI_l1aHjrmnqI2nUha4JA5eIzqPCYDL-eqnVJi5c8QGHj9yD0BnBl5QSMbFdm1NMyhzPON9DR0Rwns8YJvspc1HmRVHyEToO4RVjLtgUH6IRoxQLxtgR6uerx7v75VX2qdpY-di71lXZB_gQQ-Z2B67NPNRqHcBMPFivdN_5IdMvvmudzuqhWb90eug3GeIbNE5NQqPq-u_Vd27UCTqwqg5w-rOO0fP18mlxm68ebu4W81WuOcF9rlVRCVxwTbktsZjNpnZqlDaFISVmxloD1gIXmhkorKGUU2XSjKKqTEGAsTG62PauffceIfTytYu-TV9KmlSwkhYcJyrfUtp3IaTp5Nq7RvlBEiw3jmVyLDeO5cZx4s9_WmPVgNnRv1ITUG4BG_voIWgHrQa53aUXTrsW_in_ArC5jrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473392640</pqid></control><display><type>article</type><title>ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma</title><source>MEDLINE</source><source>PubMed Central</source><creator>Hillmen, Peter ; Brown, Jennifer R ; Eichhorst, Barbara F ; Lamanna, Nicole ; O'Brien, Susan M ; Qiu, Lugui ; Salmi, Tommi ; Hilger, James ; Wu, Kenneth ; Cohen, Aileen ; Huang, Jane ; Tam, Constantine S</creator><creatorcontrib>Hillmen, Peter ; Brown, Jennifer R ; Eichhorst, Barbara F ; Lamanna, Nicole ; O'Brien, Susan M ; Qiu, Lugui ; Salmi, Tommi ; Hilger, James ; Wu, Kenneth ; Cohen, Aileen ; Huang, Jane ; Tam, Constantine S</creatorcontrib><description>Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2019-0844</identifier><identifier>PMID: 32207333</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase - metabolism ; Anemia ; Bruton tyrosine kinase ; BTK inhibitor ; Cardiac arrhythmia ; Cardiovascular disease ; Chronic Disease ; chronic lymphocytic leukemia ; clinical trials ; Clinical Trials, Phase III as Topic ; comparative effectiveness ; Diarrhea ; Drug dosages ; FDA approval ; hematologic/leukemia ; Humans ; Hypertension ; ibrutinib ; Inhibitor drugs ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - pathology ; Lymphatic system ; Lymphoma ; Neutropenia ; Outcome Assessment, Health Care ; Piperidines - adverse effects ; Piperidines - therapeutic use ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrazoles - adverse effects ; Pyrazoles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Randomized Controlled Trials as Topic ; Risk factors ; Safety ; Targeted cancer therapy ; zanubrutinib</subject><ispartof>Future oncology (London, England), 2020-04, Vol.16 (10), p.517-523</ispartof><rights>2020 Peter Hillmen</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-ca6b7064c24f907885f5dacd6d1903dffdeffe47c3de6fd2242ad0477bbd61e33</citedby><cites>FETCH-LOGICAL-c410t-ca6b7064c24f907885f5dacd6d1903dffdeffe47c3de6fd2242ad0477bbd61e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32207333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hillmen, Peter</creatorcontrib><creatorcontrib>Brown, Jennifer R</creatorcontrib><creatorcontrib>Eichhorst, Barbara F</creatorcontrib><creatorcontrib>Lamanna, Nicole</creatorcontrib><creatorcontrib>O'Brien, Susan M</creatorcontrib><creatorcontrib>Qiu, Lugui</creatorcontrib><creatorcontrib>Salmi, Tommi</creatorcontrib><creatorcontrib>Hilger, James</creatorcontrib><creatorcontrib>Wu, Kenneth</creatorcontrib><creatorcontrib>Cohen, Aileen</creatorcontrib><creatorcontrib>Huang, Jane</creatorcontrib><creatorcontrib>Tam, Constantine S</creatorcontrib><title>ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.</description><subject>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</subject><subject>Agammaglobulinaemia Tyrosine Kinase - metabolism</subject><subject>Anemia</subject><subject>Bruton tyrosine kinase</subject><subject>BTK inhibitor</subject><subject>Cardiac arrhythmia</subject><subject>Cardiovascular disease</subject><subject>Chronic Disease</subject><subject>chronic lymphocytic leukemia</subject><subject>clinical trials</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>comparative effectiveness</subject><subject>Diarrhea</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>hematologic/leukemia</subject><subject>Humans</subject><subject>Hypertension</subject><subject>ibrutinib</subject><subject>Inhibitor drugs</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</subject><subject>Lymphatic system</subject><subject>Lymphoma</subject><subject>Neutropenia</subject><subject>Outcome Assessment, Health Care</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - therapeutic use</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk factors</subject><subject>Safety</subject><subject>Targeted cancer therapy</subject><subject>zanubrutinib</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kEtPAyEURonRWK0u3ZpJXI_l1aHjrmnqI2nUha4JA5eIzqPCYDL-eqnVJi5c8QGHj9yD0BnBl5QSMbFdm1NMyhzPON9DR0Rwns8YJvspc1HmRVHyEToO4RVjLtgUH6IRoxQLxtgR6uerx7v75VX2qdpY-di71lXZB_gQQ-Z2B67NPNRqHcBMPFivdN_5IdMvvmudzuqhWb90eug3GeIbNE5NQqPq-u_Vd27UCTqwqg5w-rOO0fP18mlxm68ebu4W81WuOcF9rlVRCVxwTbktsZjNpnZqlDaFISVmxloD1gIXmhkorKGUU2XSjKKqTEGAsTG62PauffceIfTytYu-TV9KmlSwkhYcJyrfUtp3IaTp5Nq7RvlBEiw3jmVyLDeO5cZx4s9_WmPVgNnRv1ITUG4BG_voIWgHrQa53aUXTrsW_in_ArC5jrw</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Hillmen, Peter</creator><creator>Brown, Jennifer R</creator><creator>Eichhorst, Barbara F</creator><creator>Lamanna, Nicole</creator><creator>O'Brien, Susan M</creator><creator>Qiu, Lugui</creator><creator>Salmi, Tommi</creator><creator>Hilger, James</creator><creator>Wu, Kenneth</creator><creator>Cohen, Aileen</creator><creator>Huang, Jane</creator><creator>Tam, Constantine S</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200401</creationdate><title>ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma</title><author>Hillmen, Peter ; Brown, Jennifer R ; Eichhorst, Barbara F ; Lamanna, Nicole ; O'Brien, Susan M ; Qiu, Lugui ; Salmi, Tommi ; Hilger, James ; Wu, Kenneth ; Cohen, Aileen ; Huang, Jane ; Tam, Constantine S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-ca6b7064c24f907885f5dacd6d1903dffdeffe47c3de6fd2242ad0477bbd61e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</topic><topic>Agammaglobulinaemia Tyrosine Kinase - metabolism</topic><topic>Anemia</topic><topic>Bruton tyrosine kinase</topic><topic>BTK inhibitor</topic><topic>Cardiac arrhythmia</topic><topic>Cardiovascular disease</topic><topic>Chronic Disease</topic><topic>chronic lymphocytic leukemia</topic><topic>clinical trials</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>comparative effectiveness</topic><topic>Diarrhea</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>hematologic/leukemia</topic><topic>Humans</topic><topic>Hypertension</topic><topic>ibrutinib</topic><topic>Inhibitor drugs</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - pathology</topic><topic>Lymphatic system</topic><topic>Lymphoma</topic><topic>Neutropenia</topic><topic>Outcome Assessment, Health Care</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - therapeutic use</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk factors</topic><topic>Safety</topic><topic>Targeted cancer therapy</topic><topic>zanubrutinib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hillmen, Peter</creatorcontrib><creatorcontrib>Brown, Jennifer R</creatorcontrib><creatorcontrib>Eichhorst, Barbara F</creatorcontrib><creatorcontrib>Lamanna, Nicole</creatorcontrib><creatorcontrib>O'Brien, Susan M</creatorcontrib><creatorcontrib>Qiu, Lugui</creatorcontrib><creatorcontrib>Salmi, Tommi</creatorcontrib><creatorcontrib>Hilger, James</creatorcontrib><creatorcontrib>Wu, Kenneth</creatorcontrib><creatorcontrib>Cohen, Aileen</creatorcontrib><creatorcontrib>Huang, Jane</creatorcontrib><creatorcontrib>Tam, Constantine S</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hillmen, Peter</au><au>Brown, Jennifer R</au><au>Eichhorst, Barbara F</au><au>Lamanna, Nicole</au><au>O'Brien, Susan M</au><au>Qiu, Lugui</au><au>Salmi, Tommi</au><au>Hilger, James</au><au>Wu, Kenneth</au><au>Cohen, Aileen</au><au>Huang, Jane</au><au>Tam, Constantine S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>16</volume><issue>10</issue><spage>517</spage><epage>523</epage><pages>517-523</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32207333</pmid><doi>10.2217/fon-2019-0844</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-04, Vol.16 (10), p.517-523 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_journals_2473392640 |
| source | MEDLINE; PubMed Central |
| subjects | Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Agammaglobulinaemia Tyrosine Kinase - metabolism Anemia Bruton tyrosine kinase BTK inhibitor Cardiac arrhythmia Cardiovascular disease Chronic Disease chronic lymphocytic leukemia clinical trials Clinical Trials, Phase III as Topic comparative effectiveness Diarrhea Drug dosages FDA approval hematologic/leukemia Humans Hypertension ibrutinib Inhibitor drugs Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - pathology Lymphatic system Lymphoma Neutropenia Outcome Assessment, Health Care Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Risk factors Safety Targeted cancer therapy zanubrutinib |
| title | ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T10%3A28%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ALPINE:%20zanubrutinib%20versus%20ibrutinib%20in%20relapsed/refractory%20chronic%20lymphocytic%20leukemia/small%20lymphocytic%20lymphoma&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Hillmen,%20Peter&rft.date=2020-04-01&rft.volume=16&rft.issue=10&rft.spage=517&rft.epage=523&rft.pages=517-523&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2019-0844&rft_dat=%3Cproquest_cross%3E2473392640%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473392640&rft_id=info:pmid/32207333&rfr_iscdi=true |